Loading clinical trials...

Your health journey, clearly organized.

Legal

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia | Clinical Trials | Clareo Health

TERMINATEDNA

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

NCT03473457•Zhujiang Hospital

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Relapsed/Refractory Acute Myeloid Leukemia(AML)

Interventions

CART therapy in Acute myeloid leukemia(AML)

Locations

China

Locations (1)

Southern Medical University Zhujiang Hospital

Guangdong, Guangdong, China

Key Dates

Start Date

April 1, 2018

Primary Completion Date

December 31, 2020

Completion Date

December 31, 2020

Last Updated

September 13, 2021

Sponsors

Lead Sponsor

Zhujiang Hospital

Collaborators

Nanfang Hospital, Southern Medical University
The Third Affiliated Hospital of Southern Medical University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 13, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions